Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 14.02%.

  • Protalix BioTherapeutics' EBITDA Margin fell 100300.0% to 14.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.9%, marking a year-over-year increase of 296800.0%. This contributed to the annual value of 7.34% for FY2024, which is 86400.0% down from last year.
  • Protalix BioTherapeutics' EBITDA Margin amounted to 14.02% in Q3 2025, which was down 100300.0% from 7.48% recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' EBITDA Margin registered a high of 58.22% during Q2 2023, and its lowest value of 142.62% during Q2 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 22.03% (2022), whereas its average is 27.69%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -1221900bps in 2021, then surged by 1213300bps in 2023.
  • Protalix BioTherapeutics' EBITDA Margin (Quarter) stood at 66.74% in 2021, then soared by 57bps to 28.95% in 2022, then crashed by -85bps to 53.55% in 2023, then skyrocketed by 174bps to 39.57% in 2024, then tumbled by -65bps to 14.02% in 2025.
  • Its EBITDA Margin stands at 14.02% for Q3 2025, versus 7.48% for Q2 2025 and 40.99% for Q1 2025.